Double‐blind placebo‐controlled multicenter phase II trial to evaluate D‐methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer

Hamstra, Daniel A.; Lee, Kuei C.; Eisbruch, Avraham; Sunkara, Prasad S.; Borgonha, Sudhir; Phillip, Babu; Campbell, Kathleen C.M.; Ross, Brian D.; Rehemtulla, Alnawaz

doi:10.1002/hed.25115

Cited by 21 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D-met is contained in egg albumin [111]. The first researches on D-met properties focused on its efficacy in preventing cisplatin-induced ototoxicity in rat by its specific ability to counteract oxidative stress, without affecting the tumor response to an antineoplastic agent [112][113][114][115][116]. The D-met antioxidant activity is displayed also in other areas of the body: (i) in the liver, preventing the decrease of mitochondrial glutathione levels [117]; (ii) in the CNS, improving neurogenesis of hippocampal neurons [118]; (iii) in the kidney, through elevation of antioxidative activities [119]; and (iv) in the gastrointestinal system, protecting the mucosa and the gut microbiome from cisplatin-induced imbalance [120].…”

Section: D-methioninementioning

confidence: 99%

Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies

Conte

Bresciani

Rizzi

et al. 2020

IJMS

View full text Add to dashboard Cite

Among the severe side effects induced by cisplatin chemotherapy, muscle wasting is the most relevant one. This effect is a major cause for a clinical decline of cancer patients, since it is a negative predictor of treatment outcome and associated to increased mortality. However, despite its toxicity even at low doses, cisplatin remains the first-line therapy for several types of solid tumors. Thus, effective pharmacological treatments counteracting or minimizing cisplatin-induced muscle wasting are urgently needed. The dissection of the molecular pathways responsible for cisplatin-induced muscle dysfunction gives the possibility to identify novel promising therapeutic targets. In this context, the use of animal model of cisplatin-induced cachexia is very useful. Here, we report an update of the most relevant researches on the mechanisms underlying cisplatin-induced muscle wasting and on the most promising potential therapeutic options to preserve muscle mass and function.

show abstract

Section: D-methioninementioning

confidence: 99%

Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies

Conte

Bresciani

Rizzi

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…For example, methionine-derivative S-adenosyl methionine (SAM) is a cofactor acting mainly as a methyl donor to cytosine in DNA during epigenetic modification [136]. A recent study found a reduced oral mucositis after an oral D-methionine treatment in patients with grade 3/4 HNSCCs [137]; an in vitro study showed that the administration of methionine could also downregulate the proliferative capacity in HNSCC cells; it was also reported that there was a positive correlation of high methionine serum levels with greater overall and relapse-free survival rates [121,138]. These findings suggest that methionine could be tumor-suppressive and that the methionine content might serve as a prognostic factor for HNSCC patients, although one must still mechanistically clarify the way in which methionine regulates epigenetic modification in HNSCC development.…”

Section: Development Of Anti-cancer Scheme By Targeting Distinct Mmentioning

confidence: 99%

Targeting Cellular Metabolism Modulates Head and Neck Oncogenesis

Hsieh¹,

Chen²,

Lin

et al. 2019

IJMS

View full text Add to dashboard Cite

Considering the great energy and biomass demand for cell survival, cancer cells exhibit unique metabolic signatures compared to normal cells. Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent neoplasms worldwide. Recent findings have shown that environmental challenges, as well as intrinsic metabolic manipulations, could modulate HNSCC experimentally and serve as clinic prognostic indicators, suggesting that a better understanding of dynamic metabolic changes during HNSCC development could be of great benefit for developing adjuvant anti-cancer schemes other than conventional therapies. However, the following questions are still poorly understood: (i) how does metabolic reprogramming occur during HNSCC development? (ii) how does the tumorous milieu contribute to HNSCC tumourigenesis? and (iii) at the molecular level, how do various metabolic cues interact with each other to control the oncogenicity and therapeutic sensitivity of HNSCC? In this review article, the regulatory roles of different metabolic pathways in HNSCC and its microenvironment in controlling the malignancy are therefore discussed in the hope of providing a systemic overview regarding what we knew and how cancer metabolism could be translated for the development of anti-cancer therapeutic reagents.

show abstract

“…R e p o r t s e x a m i n i n g a m i n o a c i d & a m i n o a c i d derivatives for OM are either preliminary or have shown no benefit (33)(34)(35)(36)(37)(38)(39)(40)(41). Similarly, no recommendation can be made on the use of alternative therapies.…”

Section: Discussionmentioning

confidence: 99%

Narrative review of the management of oral mucositis during chemoradiation for head and neck cancer

2021

View full text Add to dashboard Cite

Oral mucositis (OM) can be a significant problem for patients undergoing radiation or chemoradiation for head and neck cancer. In modern clinical trials, grade 3-4 OM can be seen in over 40% of patients and can cause a significant impact on their quality of life (QOL). Despite this fact, strategies for the prevention and treatment of OM vary widely, with options including both lifestyle modifications and pharmaceuticals. Here we evaluate and summarize the current clinical interventions for the management of radiation-induced OM. The majority of the current evidence focuses on reducing OM related pain.These agents are detailed over multiple clinical trials including treatment modalities such as: GC4419, doxepin mouthwash, diphenhydramine-lidocaine-antacid (DLA) mouthwash, gabapentin, and methadone.While several strategies have been employed to prevent radiation-induced OM, there is currently no strong evidence for the routine use of these agents in the clinic. After summarization of these treatments, we offer practical guidance for the treatment of OM in the clinic. We recommend a multiagent approach of pharmacological and non-pharmacological treatments including oral rinses, home humidification, escalating doses of gabapentin, doxepin or DLA mouthwash, over the counter analgesics, and lastly methadone. These interventions are tailored to address the expected increase of severity of symptoms during the course of head and neck radiotherapy.

show abstract

Double‐blind placebo‐controlled multicenter phase II trial to evaluate D‐methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer

Abstract: Although not meeting the primary end point, results of multiple assessments suggest that D-met decreased mucositis.

Cited by 21 publications

References 43 publications

Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies

Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies

Targeting Cellular Metabolism Modulates Head and Neck Oncogenesis

Narrative review of the management of oral mucositis during chemoradiation for head and neck cancer

Contact Info

Product

Resources

About